High Altitude Diabetes Protection Discovered
Analysis based on 6 articles · First reported Feb 20, 2026 · Last updated Feb 23, 2026
The discovery by Gladstone Institutes and the development of HypoxyStat could significantly impact the pharmaceutical and biotechnology industries by offering a novel approach to diabetes treatment. This breakthrough may lead to new drug development and investment opportunities in companies focusing on metabolic diseases, potentially shifting market dynamics for existing diabetes medications.
Scientists at Gladstone Institutes, led by Isha Jain, have discovered the biological mechanism behind why living at high altitudes protects against diabetes. Their research, published in Cell Metabolism, reveals that in low-oxygen environments, red blood cells switch to a new metabolic mode, absorbing large amounts of glucose from the bloodstream and acting as 'glucose sinks.' This process not only helps the body cope with thin air but also significantly reduces blood sugar levels. The team, including Yolanda Martí-Mateos, Angelo D Alessandro, and Allan Doctor, confirmed these findings through experiments in mice. Furthermore, Isha Jain's lab developed a drug called HypoxyStat, which mimics the effects of low oxygen. In diabetic mouse models, HypoxyStat completely reversed high blood sugar and outperformed existing treatments, hinting at a powerful new strategy for diabetes therapy. This discovery opens new avenues for understanding and controlling blood sugar, with potential implications beyond diabetes for exercise physiology and trauma care.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard